Meds A-Z
Moxidectin
Detailed information about Moxidectin
Pet Owner Quick Guide
Start here: what this medicine is for, what it does, and when it's usually needed.
Usually used for:
For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm ( Toxocara cati ; 4th stage larvae, immature adults and adults) and hookworm ( Ancylosto...
What it does:
To prevent infection by the canine heartworm Dirofilaria immitis and the subsequent development of canine heartworm disease. For the treatment and control of the following stages of gastrointestinal parasites in horses a...
When it's needed:
Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and p...
Call your vet sooner if you notice:
- Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result. Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals. Do not use in horses intended for human consumption. A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal.
Commonly reported reactions:
- (2 reports)
- (1 reports)
- (1 reports)
What to ask your vet today:
- Is this medicine the right fit for my pet’s current symptoms?
- Which warning signs mean I should call back right away?
- How should I handle missed doses or refusal to take the medicine?
Moxidectin
Drug type: Generic ingredient • Branded profile • FDA branded products available
Species: Both
Manufacturer: Elanco US Inc.
Quick Facts
Official label facts first, then secondary summaries. Marketing content is separated below.
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141518 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141554 · official_label · FDA application profile
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source
Warnings / Contraindications
Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result. Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals. Do not use in horses intended for human consumption. A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal.
- High: Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result. Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals. Do not use in horses intended for human consumption. A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal.
- https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source
Adverse Reactions
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Tap or hover a reaction to see what it means in plain language.
Most Reported Reactions
| Reaction | Cases | Species | Serious cases |
|---|---|---|---|
| 2 | Cat, Dog | 0 | |
| 1 | Dog | 1 | |
| 1 | Dog | 1 | |
| 1 | Dog | 1 | |
| 1 | Dog | 1 | |
| 1 | Dog | 1 | |
| 1 | Cat | 1 | |
| 1 | Cat | 1 |
Species coverage: Cat (24) Dog (8)
View detailed reaction table
| Reaction | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|
| Cat | Non-serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Dog | Non-serious | - | 1 | |
| Dog | Serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Cat | Non-serious | - | 1 | |
| Dog | Unknown | - | - | |
| Cat | Unknown | - | - | |
| Cat | Unknown | - | - | |
| Cat | Unknown | - | - | |
| Cat | Unknown | - | - | |
| Cat | Unknown | - | - | |
| Cat | Unknown | - | - | |
| Cat | Unknown | - | - |
- https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-054396
Storage & Handling
No storage/handling guidance is linked yet.
Documents
Official label facts are separated from secondary summaries.
Official documents: 86 • Secondary summaries: 0
- FOI Summary sN 141-518 Approved January 13, 2026.pdf · FOI
- FOI Summary sN 141-518 Approved August 9, 2022.pdf · FOI
- FOI Summary oN 141-518 Approved November 14, 2019_.pdf · FOI
- BRAVECTO® PLUS · SPL
- FOI Summary sN 141-554 Approved January 20, 2026.pdf · FOI
- FOI Summary sN 141-554 Approved April 23 2025_EF.pdf · FOI
- FOI Summary sN 141-554 Approved October 7, 2024.pdf · FOI
- FOI Summary oN 141-554 Approved July 19, 2023.pdf · FOI
- NexGard® PLUS · SPL
- FOI Summary o 141-619 Approved December 17, 2025 (2).pdf · FOI
- Credelio Quattro™-CA1 · SPL
- ANADA 200-700 FOI Summar.pdf · FOI
- PARASEDGE® Multi for Dogs · SPL
- FOI Summary oA 200-714 Approved November 24, 2021.pdf · FOI
- Barrier® for cats · SPL
- FOI Summary sN 141-581 Approved October 20, 2025.pdf · FOI
- FOI Summary sN 141-581 Approved May 21, 2025.pdf · FOI
- FOI Summary oN 141-581 Approved October 7, 2024.pdf · FOI
- Credelio Quattro™ · SPL
- FOI Summary oA 200-818 Approved August 5, 2025.pdf · FOI
- MoxiCloprid™ for Dogs · SPL
- FOI Summary sN 141-521 Approved April 8 2025_ceg_ef.pdf · FOI
- FOI Summary sN 141-521 Approved November 6, 2024.pdf · FOI
- FOI Summary sN 141-521 Approved December 23, 2021.sum.pdf · FOI
- FOI Summary oN 141-521 Approved February 27, 2020.pdf · FOI
- Simparica TRIO® · SPL
- FOI Summary oA 200-718 Approved February 7, 2022.pdf · FOI
- Barrier® for dogs · SPL
- FOI Summary oA 200-811 Approved March 24, 2025.pdf · FOI
- MoxiCloprid™ for Cats · SPL
- FOI Summary oA 200-788 Approved July 2, 2024.pdf · FOI
- MoxiSolv™ Injection · SPL
- FOI Summary sA 200-701 Approved February 9, 2023.pdf · FOI
- FOI Summary oA 200-701 Approved June 10, 2021.pdf · FOI
- PARASEDGE™ Multi for Cats · SPL
- FOI Summary sA 200-721 Approved January 12, 2023.pdf · FOI
- FOI Summary oA 200-721 Approved March 28, 2022.pdf · FOI
- Midamox® for Cats · SPL
- ucm117079.pdf · FOI
- ucm117077.pdf · FOI
- ucm117074.pdf · FOI
- ucm117068.pdf · FOI
- N141087_Orig_7_11_1997.pdf · FOI
- Quest® Gel · SPL
- UCM457309.pdf · FOI
- ucm118023.pdf · FOI
- ucm118021.pdf · FOI
- ucm118019.pdf · FOI
- Quest® Plus Gel · SPL
- FOI Summary oA 200-716 Approved January 28, 2022.pdf · FOI
- Midamox® for Dogs · SPL
- FOI Summary oA 200-746 Approved March 30, 2023.pdf · FOI
- Tauramox™ · SPL
- UCM381705.pdf · FOI
- UCM051438.pdf · FOI
- Advantage Multi™ for Dogs · SPL
- UCM381709.pdf · FOI
- UCM051423.pdf · FOI
- advantage multi™ for cats · SPL
- ucm117120.pdf · FOI
- ucm117119.pdf · FOI
- UCM355528.pdf · FOI
- 141-099 · EA
- 141-099 · FONSI
- Cydectin™ (moxidectin) Pour-On for Beef and Dairy Cattle · SPL
- UCM117595.pdf · FOI
- ucm117593.pdf · FOI
- ucm117588.pdf · FOI
- Final Version PROHEART6 N141189C0137.pdf · Labeling
- Final Version PROHEART6 N141189C0137.pdf · Labeling
- ProHeart® 6 · SPL
- ucm051488.pdf · FOI
- Cydectin® Oral Drench for Sheep · SPL
- FOI Summary oA 200-638 Approved May 27, 2020.pdf · FOI
- IMOXI™ Topical Solution for Cats · SPL
- FOI Summary oA 200-615 Approved December 19, 2019.pdf · FOI
- IMOXI™ Topical Solution for Dogs · SPL
- N141051 Orig_5_27_1997_..pdf · FOI
- ProHeart™ · SPL
- ucm118029.pdf · FOI
- ucm118028.pdf · FOI
- 141-220 · EA
- 141-220 · FONSI
- Cydectin® · SPL
- UCM453544.pdf · FOI
- CORAXIS™ · SPL
No source yet.
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17871 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/12752 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/7947 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/7989/BRAVECTO%C2%AE%20PLUS · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17910 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/16845 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/15947 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/14288 · document · FOI
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/14516/NexGard%C2%AE%20PLUS · document · SPL
- https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17789 · document · FOI
Promotional Materials (Marketing)
This content is marketing material and not clinical guidance.
No marketing assets are linked yet.
No source yet.
Technical appendix (vet reference)
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
At a Glance
Quick facts and links to official labeling and safety signals.
- Medication catalog: Source PetWisePlus | Refreshed Feb 12, 2026, 10:44 PM UTC
-
Animal Drugs @ FDA:
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Applications/products are imported from FDA export data.
-
Animal Drugs @ FDA previews:
Source FDA
| Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
-
Animal Drug Product Listing Directory (NDC):
Source FDA
| Refreshed Feb 16, 2026, 11:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
- openFDA reaction terms: Source FDA openFDA | Refreshed Feb 16, 2026, 11:02 AM UTC
- openFDA case summaries: Source FDA openFDA | Refreshed Feb 12, 2026, 10:42 PM UTC
Counseling and Monitoring Highlights
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
- Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result. Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals. Do not use in horses intended for human consumption. A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal. (Contraindication, High)
Identifiers & Packages
Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.
| Package NDC | Product NDC | Form / Route | Status |
|---|---|---|---|
| 0010-4260-01 | 0010 | - | |
| 0010-4260-02 | 0010 | - | |
| 0010-4260-03 | 0010 | - | |
| 0010-4261-01 | 0010 | - | |
| 0010-4261-02 | 0010 | - | |
| 0010-4261-03 | 0010 | - | |
| 0010-4262-01 | 0010 | - | |
| 0010-4262-02 | 0010 | - | |
| 0010-4262-03 | 0010 | - | |
| 0010-4263-01 | 0010 | - | |
| 0010-4263-02 | 0010 | - | |
| 0010-4263-03 | 0010 | - | |
| 0010-4264-01 | 0010 | - | |
| 0010-4264-02 | 0010 | - | |
| 0010-4264-03 | 0010 | - | |
| 0061-5996-01 | 0061 | - | |
| 0061-5997-01 | 0061 | - | |
| 0061-5998-01 | 0061 | - | |
| 17030-023-01 | 17030 | - | |
| 17030-023-03 | 17030 | - |
Enriched Documents
Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.
-
FOI Summary oN 141-554 Approved July 19, 2023.pdf
• FOI summary • Official
• Feb. 2, 2026
FDA FOI summary for application 141554
-
FOI Summary sN 141-554 Approved October 7, 2024.pdf
• FOI summary • Official
• Feb. 2, 2026
FDA FOI summary for application 141554
-
FOI Summary sN 141-554 Approved April 23 2025_EF.pdf
• FOI summary • Official
• Feb. 2, 2026
FDA FOI summary for application 141554
-
FOI Summary sN 141-554 Approved January 20, 2026.pdf
• FOI summary • Official
• Feb. 2, 2026
FDA FOI summary for application 141554
-
FOI Summary oN 141-518 Approved November 14, 2019_.pdf
• FOI summary • Official
• Feb. 2, 2026
FDA FOI summary for application 141518
-
FOI Summary sN 141-518 Approved August 9, 2022.pdf
• FOI summary • Official
• Feb. 2, 2026
FDA FOI summary for application 141518
-
FOI Summary sN 141-518 Approved January 13, 2026.pdf
• FOI summary • Official
• Feb. 2, 2026
FDA FOI summary for application 141518
-
FOI Summary o 141-619 Approved December 17, 2025 (2).pdf
• FOI summary • Official
• Jan. 5, 2026
FDA FOI summary for application 141619
-
ANADA 200-700 FOI Summar.pdf
• FOI summary • Official
• Dec. 16, 2025
FDA FOI summary for application 200700
-
FOI Summary oA 200-714 Approved November 24, 2021.pdf
• FOI summary • Official
• Dec. 5, 2025
FDA FOI summary for application 200714
-
FOI Summary oN 141-581 Approved October 7, 2024.pdf
• FOI summary • Official
• Nov. 3, 2025
FDA FOI summary for application 141581
-
FOI Summary sN 141-581 Approved May 21, 2025.pdf
• FOI summary • Official
• Nov. 3, 2025
FDA FOI summary for application 141581
-
FOI Summary sN 141-581 Approved October 20, 2025.pdf
• FOI summary • Official
• Nov. 3, 2025
FDA FOI summary for application 141581
-
FOI Summary oA 200-818 Approved August 5, 2025.pdf
• FOI summary • Official
• Aug. 28, 2025
FDA FOI summary for application 200818
-
FOI Summary oN 141-521 Approved February 27, 2020.pdf
• FOI summary • Official
• June 3, 2025
FDA FOI summary for application 141521
-
FOI Summary sN 141-521 Approved December 23, 2021.sum.pdf
• FOI summary • Official
• June 3, 2025
FDA FOI summary for application 141521
-
FOI Summary sN 141-521 Approved November 6, 2024.pdf
• FOI summary • Official
• June 3, 2025
FDA FOI summary for application 141521
-
FOI Summary sN 141-521 Approved April 8 2025_ceg_ef.pdf
• FOI summary • Official
• June 3, 2025
FDA FOI summary for application 141521
-
FOI Summary oA 200-718 Approved February 7, 2022.pdf
• FOI summary • Official
• June 2, 2025
FDA FOI summary for application 200718
-
FOI Summary oA 200-811 Approved March 24, 2025.pdf
• FOI summary • Official
• March 28, 2025
FDA FOI summary for application 200811
-
FOI Summary oA 200-788 Approved July 2, 2024.pdf
• FOI summary • Official
• Aug. 1, 2024
FDA FOI summary for application 200788
-
FOI Summary oA 200-701 Approved June 10, 2021.pdf
• FOI summary • Official
• Oct. 24, 2023
FDA FOI summary for application 200701
-
FOI Summary sA 200-701 Approved February 9, 2023.pdf
• FOI summary • Official
• Oct. 24, 2023
FDA FOI summary for application 200701
-
FOI Summary oA 200-721 Approved March 28, 2022.pdf
• FOI summary • Official
• Oct. 10, 2023
FDA FOI summary for application 200721
-
FOI Summary sA 200-721 Approved January 12, 2023.pdf
• FOI summary • Official
• Oct. 10, 2023
FDA FOI summary for application 200721
-
ucm118019.pdf
• FOI summary • Official
• Sept. 19, 2023
FDA FOI summary for application 141216
-
ucm118021.pdf
• FOI summary • Official
• Sept. 19, 2023
FDA FOI summary for application 141216
-
ucm118023.pdf
• FOI summary • Official
• Sept. 19, 2023
FDA FOI summary for application 141216
-
UCM457309.pdf
• FOI summary • Official
• Sept. 19, 2023
FDA FOI summary for application 141216
-
N141087_Orig_7_11_1997.pdf
• FOI summary • Official
• Sept. 19, 2023
FDA FOI summary for application 141087
-
ucm117068.pdf
• FOI summary • Official
• Sept. 19, 2023
FDA FOI summary for application 141087
-
ucm117074.pdf
• FOI summary • Official
• Sept. 19, 2023
FDA FOI summary for application 141087
-
ucm117077.pdf
• FOI summary • Official
• Sept. 19, 2023
FDA FOI summary for application 141087
-
ucm117079.pdf
• FOI summary • Official
• Sept. 19, 2023
FDA FOI summary for application 141087
-
FOI Summary oA 200-716 Approved January 28, 2022.pdf
• FOI summary • Official
• Aug. 23, 2023
FDA FOI summary for application 200716
-
FOI Summary oA 200-746 Approved March 30, 2023.pdf
• FOI summary • Official
• April 3, 2023
FDA FOI summary for application 200746
-
UCM051438.pdf
• FOI summary • Official
• Feb. 2, 2023
FDA FOI summary for application 141251
-
UCM381705.pdf
• FOI summary • Official
• Feb. 2, 2023
FDA FOI summary for application 141251
-
UCM051423.pdf
• FOI summary • Official
• Aug. 22, 2022
FDA FOI summary for application 141254
-
UCM381709.pdf
• FOI summary • Official
• Aug. 22, 2022
FDA FOI summary for application 141254
Data Sources & Revision History
Every non-trivial field is expected to include provenance and update timestamps.
- contraindications: Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral… (Official, 2026-02-12)
- side_effects: Top reported reactions (openFDA): Lack of efficacy (endoparasite) - heartworm, Vomiting, Lack of efficacy (endoparasite) - hookworm, Lethargy (see also Central… (Official, 2026-02-12)
- usage: To prevent infection by the canine heartworm Dirofilaria immitis and the subsequent development of canine heartworm disease. For the treatment and control of t… (Official, 2026-02-12)
- side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
- contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
- usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
FDA Products & Applications (Animal Drugs @ FDA)
Official sponsor/proprietary-name/application-status records linked by active ingredient.
| Product | Sponsor | Application | Status | Published |
|---|---|---|---|---|
|
BRAVECTO® PLUS
RX
Fluralaner Moxidectin
Solution
• Topical
|
Intervet, Inc. | NADA 141-518 | Approved | Feb 2, 2026 |
|
NexGard® PLUS
RX
Afoxolaner Moxidectin Pyrantel Pamoate
Chewable Tablets
• Oral
|
Boehringer lngelheim Animal Health USA, Inc. | NADA 141-554 | Approved | Feb 2, 2026 |
|
Credelio Quattro™-CA1
RX
Lotilaner Moxidectin Praziquantel Pyrantel Pamoate
Chewable Tablets
• Oral
|
Elanco US Inc. | NADA 141-619 | Approved | Jan 5, 2026 |
|
PARASEDGE® Multi for Dogs
RX
Imidacloprid Moxidectin
Topical Solution
• Topical
|
Virbac AH, Inc. | ANADA 200-700 | Approved | Dec 16, 2025 |
|
Barrier® for cats
RX
Imidacloprid Moxidectin
Topical Solution
• Topical
|
Aurora Pharmaceutical, Inc. | ANADA 200-714 | Approved | Dec 5, 2025 |
|
Credelio Quattro™
RX
Lotilaner Moxidectin Praziquantel Pyrantel Pamoate
Chewable Tablets
• Oral
|
Elanco US Inc. | NADA 141-581 | Approved | Nov 3, 2025 |
|
MoxiCloprid™ for Dogs
RX
Imidacloprid Moxidectin
Topical Solution
• Topical
|
Bimeda Animal Health Limited | ANADA 200-818 | Approved | Aug 28, 2025 |
|
Simparica TRIO®
RX
Moxidectin Pyrantel Pamoate Sarolaner
Chewable Tablets
• Oral
|
Zoetis Inc. | NADA 141-521 | Approved | Jun 3, 2025 |
|
Barrier® for dogs
RX
Imidacloprid Moxidectin
Topical Solution
• Topical
|
Aurora Pharmaceutical, Inc. | ANADA 200-718 | Approved | Jun 2, 2025 |
|
MoxiCloprid™ for Cats
RX
Imidacloprid Moxidectin
Topical Solution
• Topical
|
Bimeda Animal Health Limited | ANADA 200-811 | Approved | Mar 28, 2025 |
|
MoxiSolv™ Injection
OTC
Moxidectin
Injectable Solution
• Subcutaneous
|
Bimeda Animal Health Limited | ANADA 200-788 | Approved | Aug 1, 2024 |
|
PARASEDGE™ Multi for Cats
RX
Imidacloprid Moxidectin
Topical Solution
• Topical
|
Virbac AH, Inc. | ANADA 200-701 | Approved | Oct 24, 2023 |
|
Midamox® for Cats
RX
Imidacloprid Moxidectin
Topical Solution
• Topical
|
Norbrook Laboratories, Ltd. | ANADA 200-721 | Approved | Oct 10, 2023 |
|
Quest® Gel
OTC
Moxidectin
Gel
• Oral
|
Zoetis Inc. | NADA 141-087 | Approved | Sep 19, 2023 |
|
Quest® Plus Gel
OTC
Moxidectin Praziquantel
Gel
• Oral
|
Zoetis Inc. | NADA 141-216 | Approved | Sep 19, 2023 |
|
Midamox® for Dogs
RX
Imidacloprid Moxidectin
Topical Solution
• Topical
|
Norbrook Laboratories, Ltd. | ANADA 200-716 | Approved | Aug 23, 2023 |
|
Tauramox™
OTC
Moxidectin
Injectable Solution
• Subcutaneous
|
Norbrook Laboratories, Ltd. | ANADA 200-746 | Approved | Apr 3, 2023 |
|
Advantage Multi™ for Dogs
RX
Imidacloprid Moxidectin
Liquid (Solution)
• Topical
|
Elanco US Inc. | NADA 141-251 | Approved | Feb 2, 2023 |
|
advantage multi™ for cats
RX
Imidacloprid Moxidectin
Solution
• Topical
|
Elanco US Inc. | NADA 141-254 | Approved | Aug 22, 2022 |
|
Cydectin™ (moxidectin) Pour-On for Beef and Dairy Cattle
OTC
Moxidectin
Solution
• Transdermal
|
Elanco US Inc. | NADA 141-099 | Approved | Jun 8, 2022 |
|
ProHeart® 6
RX
Moxidectin
Microspheres
• Subcutaneous
|
Zoetis Inc. | NADA 141-189 | Approved | May 17, 2021 |
|
Cydectin® Oral Drench for Sheep
OTC
Moxidectin
Liquid (Solution)
• Oral
|
Elanco US Inc. | NADA 141-247 | Approved | Jan 12, 2021 |
|
IMOXI™ Topical Solution for Cats
RX
Imidacloprid Moxidectin
Topical Solution
• Topical
|
Vetoquinol USA, Inc. | ANADA 200-638 | Approved | Jun 1, 2020 |
|
IMOXI™ Topical Solution for Dogs
RX
Imidacloprid Moxidectin
Topical Solution
• Topical
|
Vetoquinol USA, Inc. | ANADA 200-615 | Approved | Dec 30, 2019 |
|
ProHeart™
RX
Moxidectin
Tablet
• Oral
|
Zoetis Inc. | NADA 141-051 | Approved | Jun 18, 2018 |
|
Cydectin®
OTC
Moxidectin
Liquid (Solution)
• Subcutaneous
|
Elanco US Inc. | NADA 141-220 | Approved | Dec 18, 2017 |
|
CORAXIS™
RX
Moxidectin
Solution
• Topical
|
Elanco US Inc. | NADA 141-417 | Approved | Jun 1, 2016 |
Data source: FDA Animal Drugs @ FDA (public search export).
What It's For (FDA Label Highlights)
Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.
Composition / specifications
For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati; 4th stage larvae, immature adults and adults) and hookworm (Ancylostoma tubaeforme; 4th stage larvae, immature adults and adults). Kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), Haemaphysalis longicornis (Asian longhorned tick), and Amblyomma maculatum (Gulf Coast tick)] for 2 months in cats and kittens 6 months of age and older and weighing 2.6 lb or greater.
Administer topically as a single dose every 2 months to provide a minimum dose of 18.2 mg/lb (40 mg/kg) fluralaner and 0.9 mg/lb (2 mg/kg) moxidectin.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of adult hookworm (Ancylostoma caninum, Ancylostoma braziliense, and Uncinaria stenocephala) and roundworm (Toxocara canis and Toxascaris leonina) infections. Kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of Ixodes scapularis (blacklegged tick), Rhipicephalus sanguineus (brown dog tick), Dermacentor variabilis (American dog tick), Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), and Haemaphysalis longicornis (longhorned tick) infestations for one month in dogs and puppies eight weeks of age and older, weighing four pounds of body weight or greater. For the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.
Administer orally once a month at the minimum dose of 1.14 mg/lb (2.5 mg/kg) afoxolaner, 5.45 mcg/lb (12 mcg/kg) moxidectin, and 2.27 mg/lb (5.0 mg/kg) pyrantel (as pamoate salt). For heartworm disease prevention, give once monthly for at least six months after last exposure to mosquitoes.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies 8 weeks of age and older, and weighing 3.3 pounds or greater.
Administer orally at the minimum dosage of 9 mg/lb (20 mg/kg) lotilaner, 0.009 mg/lb (0.02 mg/kg) moxidectin, 2.28 mg/lb (5 mg/kg) praziquantel, and 2.28 mg/lb (5 mg/kg) pyrantel (as pamoate salt).
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). For the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. It is also indicated for the treatment and control of the following intestinal parasites: adult, immature adult and fourth stage larvae in hookworm species (Ancylostoma caninum and Uncinaria stenocephala); adult and fourth stage larvae in roundworm species (Toxocara canis); and adult stage in roundworm species (Toxascaris leonina) and whipworm (Trichuris vulpis).
The recommended minimum dose is 4.5 mg/lb. (10 mg/kg) imidacloprid and 1.1mg/lb. (2.5 mg/kg) moxidectin, once a month, by topical administration.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. For the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancylostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxocara cati).
The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration.
For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenophalides felis) and is indicated for the treatment of flea infestations on ferrets.
The recommended minimum dose for a ferret is 9 m/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2 mg/kg) moxidectin, once a month, by topical administration.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
Credelio Quattro™ is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina), hookworm (fourth stage larvae, immature adult, and adult Ancylostoma caninum and adult Uncinaria stenocephala), and tapeworm (Dipylidium caninum, Taenia pisiformis, and Echinococcus granulosus) infections. Credelio Quattro™ kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma Americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), and Haemaphysalis longicornis (longhorned tick)] for one month in dogs and puppies 8 weeks of age and older, and weighing 3.3 pounds or greater. Credelio Quattro™ is indicated for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.
Administer orally once a month, at the minimum dosage of 9 mg/lb (20 mg/kg) lotilaner, 0.009 mg/lb (0.02 mg/kg) moxidectin, 2.28 mg/lb (5 mg/kg) praziquantel, and 2.28 mg/lb (5 mg/kg) pyrantel (as pamoate salt).
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the prevention of heartworm disease caused by Dirofilaria immitis; and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; and the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis); kills adult fleas and treats flea infestations (Ctenocephalides felis); treats and controls sarcoptic mange caused by Sarcoptes scabiei var. canis.
The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
Simparica TRIO® is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina) and hookworm (L4, immature adult, and adult Ancylostoma caninum and adult Uncinaria stenocephala) infections. Simparica TRIO® kills adult fleas (Ctenocephalides felis) and is indicated for the treatment and prevention of flea infestations, the prevention of Dipylidium caninum (tapeworm) infections as a direct result of killing Ctenocephalides felis vector fleas on the treated dog, and the treatment and control of tick infestations with Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), and Haemaphysalis longicornis (Asian longhorned tick) for one month in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds or greater. Simparica TR O® is indicated for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.
SimparicaTRIO® is given orally, once a month, at the recommended minimum dose of 0.54 mg/lb (1.2 mg/kg) sarolaner, 0.011 mg/lb (24 µg/kg) moxidectin, and 2.27 mg/lb (5 mg/kg) pyrantel (as pamoate salt).
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis); for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis; and for the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).
The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the prevention of heartworm disease caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations, intestinal roundworms (Toxocara cati), and hookworms (Ancylostoma tubaeforme).
The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration.
For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.
The recommended minimum dose is 9 mg/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2 mg/kg) moxidectin, once a month, by topical administration.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment and control of the following internal and external parasites of cattle:
Gastrointestinal Roundworms
Ostertagia ostertagi - Adults and L4 (including inhibited Larvae)
Haemonchus placei - Adults
Trichostrongylus axei - Adults and L4
Trichostrongylus colubriformis - Adults and L4
Cooperia oncophora - Adults
Cooperia pectinata - Adults
Cooperia punctata - Adults and L4
Cooperia spatulata - Adults
Cooperia surnabada - Adults and L4
Nematodirus helvetianus - Adults
Oesophagostomum radiatum - Adults and L4
Trichuris spp. - Adults
Lungworms
Dictyocaulus viviparus - Adults and L4
Cattle Grubs
Hypoderma bovis
Hypoderma lineatum
Mites
Psoroptes ovis
(Psoroptes communis var. bovis)
Lice
Linognathus vituli
Solenopotes capillatus
Persistent Activity
Moxidectin injectable has been proven to effectively protect cattle from reinfection with Dictyocaulus viviparus and Oesophagostomum radiatum for 42 days after treatment, Haemonchus placei for 35 days after treatment, and Ostertagia ostertagi and Trichostrongylus axei for 14 days after treatment.
1 mL for each 110 lb (50 kg) body weight to provide 0.2 mg moxidectin/2.2 lb (0.2 mg/kg) body weight.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancyclostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxacara cati).
The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 0.45 mg/lb (1 mg/kg) moxidectin, once a month, by topical administration.
For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.
9 mg/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2 mg/kg) moxidectin, once a month, by topical administration. Only
the 0.4 mL applicator tube volume (PARASEDGE™ Multi 9) should be used on ferrets.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the prevention of heartworm disease caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations, intestinal roundworms (Toxocara cati), and hookworms (Ancylostoma tubaeforme).
The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration.
For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.
The recommended minimum dose for a ferret is 9 mg/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2mg/kg) moxidectin, once a month, by topical administration. Only the 0.4 mL applicator volume (Midamox 9) should be used on ferrets.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment and control of the following stages of gastrointestinal parasites in horses and ponies: Large Strongyles: Strongylus vulgaris: (adults and L4 / L5 arterial stages), Strongylus edentatus: (adults and tissue stages), Triodontophorus brevicauda: (adults), Triodontophorus serratus: (adults) Small Strongyles (adults): Cyathostomum spp., including Cyathostomum catinatum, Cyathostomum pateratum Cylicostephanus spp., including Cylicostephanus calicatus, Cylicostephanus goldi, Cylicostephanus longibursatus, Cylicostephanus minutus Cylicocyclus spp., including Cylicocyclus insigne, Cylicocyclus leptostomum, Cylicocyclus nassatus, Cylicocyclus radiatus Coronocyclus spp., including Coronocyclus coronatus, Coronocyclus labiatus, Coronocyclus labratus, Gyalocephalus capitatus, Petrovinema poculatus Small Strongyles: Undifferentiated lumenal larvae Encysted cyathostomes: Late L3 and L4 mucosal cyathostome larvae Ascarids: Parascaris equorum: (adults and L4 larval stages) Pinworms: Oxyuris equi: (adults and L4 larval stages) Hairworms: Trichostrongylus axei: (adults) Large-mouth stomach worms: Habronema muscae: (adults) Horse stomach bots: Gasterophilus intestinalis: (2nd and 3rd instars), Gasterophilus nasalis: (3rd instars) One administration of the recommended dose rate of QUEST (moxidectin) 2% Equine Oral Gel also suppresses strongyle egg production through 84 days. QUEST is indicated for use in horses and ponies, including breeding mares and stallions, and foals six months of age and older.
QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result. Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals. Do not use in horses intended for human consumption.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For oral use in horses and ponies 6 months of age and older. Do not use in horses intended for human consumption.QUEST PLUS Gel has been formulated specifically for use in horses and ponies only.Reproductive safety studies on breeding stallions have not been conducted.This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result.Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis); for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis; and for the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).
The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the treatment and control of the following internal and external parasites of cattle:
Gastrointestinal Roundworms
Ostertagia ostertagi – Adults and L4 (including inhibited Larvae)
Haemonchus placei – Adults
Trichostrongylus axei – Adults and L4
Trichostrongylus colubriformis – Adults and L4
Cooperia oncophora – Adults
Cooperia pectinata – Adults
Cooperia punctata – Adults and L4
Cooperia spatulata – Adults
Cooperia surnabada – Adults and L4
Nematodirus helvetianus – Adults
Oesophagostomum radiatum – Adults and L4
Trichuris spp. – Adults
Lungworms
Dictyocaulus viviparus – Adults and L4
Cattle Grubs
Hypoderma bovis
Hypoderma lineatum
Mites
Psoroptes ovis (Psoroptes communis var. bovis)
Lice
Linognathus vituli
Solenopotes capillatus
Persistent Activity: Moxidectin Injectable has been proven to effectively protect cattle from reinfection with Dictyocaulus viviparus and Oesophagostomum radiatum for 42 days after treatment, Haemonchus placei for 35 days after treatment, and Ostertagia ostertagi and Trichostrongylus axei for 14 days after treatment.
Administer by subcutaneous injection 1 mL for each 110 lb (50 kg) body weight to provide 0.2 mg moxidectin/2.2 lb (0.2 mg/kg) body weight.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
Do not administer this product orally. For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals. Federal Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use this product (containing 2.5 %moxidectin) on cats.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
Apply 4.5 mg/lb body weight (10 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancylostoma tubaeforme); and adult and fourth stage larvae in roundworm (Toxocara cati).
The recommended minimum dose is 4.5 mg/lb. (10.0 mg/kg) imidacloprid and 0.45 mg/lb. (1.0 mg/kg) moxidectin, once a month, by topical administration.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). For the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. For the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).
The recommended minimum dose is 4.5 mg/lb. (10 mg/kg) imidacloprid and 1.1 mg/lb. (2.5 mg/kg) moxidectin, once a month, by topical administration.
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
FDA page: Open in Animal Drugs @ FDA
Composition / specifications
FDA page: Open in Animal Drugs @ FDA
Official Documents (FDA)
Direct links to FDA-hosted PDFs and SPL packages (when available).
-
Summary
This supplement provides for the addition of the indication for the treatment and control of Amblyomma maculatum (Gulf Coast tick) infestations for 2 months in cats and kittens 6 months of age and older and weighing 2.6 pounds or greater.
-
Summary
This supplement provides for the addition of the indication for the treatment and control of Haemaphysalis longicornis (Asian longhorned tick) infestations for 2 months in cats and kittens 6 months of age and older and weighing 2.6 pounds or greater.
-
Summary
For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage larvae, immature adults, and adults) and hookworm (Ancylostoma tubaeforme, 4th stage larvae, immature adults, and adults); kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations (Ixodes scapularis (black-legged tick) and Dermacentor variabilis (American dog tick)) for 2 months in cats and kittens 6 months of age and older and weighing 2.6 lb or greater.
- BRAVECTO® PLUS (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
This supplement provides for the addition of the indication for the treatment and control of Amblyomma maculatum (Gulf Coast tick) infestations for one month in dogs and puppies eight weeks of age and older, weighing four pounds of body weight or greater.
-
Summary
This supplement provides for the addition of the indication for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.
-
Summary
This supplement provides for the addition of the indication for the treatment and control of Haemaphysalis longicornis (longhorned tick) infestations in dogs and puppies eight weeks of age and older, weighing four pounds of body weight or greater, for one month. This supplement also provides for the addition of label language regarding the results of a second flea field study and improvement of erythema, alopecia, papules, scales, crusts, and excoriation in dogs with flea infestations and signs of Flea Allergy Dermatitis following treatment with afoxolaner alone, as a direct result of eliminating fleas.
-
Summary
For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of adult hookworm (Ancylostoma caninum, Ancylostoma braziliense, and Uncinaria stenocephala) and roundworm (Toxocara canis and Toxascaris leonina) infections. Kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), Dermacentor variabilis (American dog tick), and Amblyomma americanum (lone star tick) infestations for one month in dogs and puppies eight weeks of age and older, weighing four pounds of body weight or greater.
- NexGard® PLUS (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies 8 weeks of age and older, and weighing 3.3 pounds or greater.
- Credelio Quattro™-CA1 (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). For the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. It is also indicated for the treatment and control of the following intestinal parasites: adult, immature adult and fourth stage larvae in hookworm species (Ancylostoma caninum and Uncinaria stenocephala); adult and fourth stage larvae in roundworm species (Toxocara canis); and adult stage in roundworm species (Toxascaris leonina) and whipworm (Trichuris vulpis).
FDA page: Open in Animal Drugs @ FDA
-
Summary
Cats: For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. For the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancylostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxocara cati).
Ferrets: For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenophalides felis) and is indicated for the treatment of flea infestations on ferrets.
- Barrier® for cats (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
This supplement provides for the addition of the indication for the treatment and control of Haemaphysalis longicornis (longhorned tick) tick infestations for one month in dogs and puppies 8 weeks of age and older, weighing 3.3 pounds or greater, and for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.
-
Summary
This supplement provides for the addition of the indication for the treatment and control of hookworm (fourth stage larvae, immature adult, and adult Ancylostoma caninum) infections in dogs and puppies 8 weeks of age and older, and weighing 3.3 pounds or greater.
-
Summary
For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina), hookworm (adult Uncinaria stenocephala), and tapeworm (Dipylidium caninum, Taenia pisiformis, and Echinococcus granulosus) infections. Kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), and Rhipicephalus sanguineus (brown dog tick)] for one month in dogs and puppies 8 weeks of age and older, and weighing 3.3 pounds or greater.
- Credelio Quattro™ (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the prevention of heartworm disease caused by Dirofilaria immitis; and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; and the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis); kills adult fleas and treats flea infestations (Ctenocephalides felis); treats and controls sarcoptic mange caused by Sarcoptes scabiei var. canis.
- MoxiCloprid™ for Dogs (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
This supplement provides for the addition of the indication for the prevention of Dipylidium caninum (tapeworm) infections as a direct result of killing Ctenocephalides felis vector fleas on the treated dog for one month in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds or greater.
-
Summary
This supplement provides for the addition of the indication for the treatment and control of Haemaphysalis longicornis (Asian longhorned tick) infestations for one month in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds or greater.
-
Summary
This supplement provides for the addition of the indications, for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks and for the treatment and control of L4 and immature adult Ancylostoma caninum.
-
Summary
Simparica Trio® is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina) and adult hookworm (Ancylostoma caninum and Uncinaria stenocephala) infections. Simparica Trio® kills adult fleas (Ctenocephalides felis) and is indicated for the treatment and prevention of flea infestations, the treatment and control of tick infestations with Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), and Rhipicephalus sanguineus (brown dog tick) for one month in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds or greater.
- Simparica TRIO® (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis); for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis; and for the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).
- Barrier® for dogs (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
Cats: For the prevention of heartworm disease caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations, intestinal roundworms (Toxocara cati), and hookworms (Ancylostoma tubaeforme).
Ferrets: For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.
- MoxiCloprid™ for Cats (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the treatment and control of internal and external parasites of cattle.
- MoxiSolv™ Injection (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
This supplement provides for the addition of the following indications for ferrets: For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.
-
Summary
For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancyclostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxacara cati).
FDA page: Open in Animal Drugs @ FDA
-
Summary
This supplement provides for the addition of the following indications for ferrets: For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.
-
Summary
For the prevention of heartworm disease caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations, intestinal roundworms (Toxocara cati), and hookworms (Ancylostoma tubaeforme).
- Midamox® for Cats (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
FOI ucm117079.pdf
Summary
The supplement provides for the use of moxidectin gel for the treatment and control of adult Cylicocyclus radiatus and Petrovinema poculatus based on results from additional dose confirmation studies. -
FOI ucm117077.pdf
Summary
For the treatment and control of the following stages of gastrointestinal parasites of horses and ponies six months of age and older which will not to be used for food: Large strongyles: Strongylus vulgaris (adult and L4/L5 arterial stages), Strongylus edentatus (adult and tissue stages), Triodontophorus brevicauda (adults), Triodontophorus serratus (adults) Small strongyles (adults): Cyathostomum spp. including C. catinatum, C. pateratum; Cylicocyclus spp. including C. insigne, C. leptostomum, C. nassatus; Cylicostephanus spp. including C.calicatus, C. goldi, C. longibursatus, C. minutis; Coronocyclus spp., including C. coronatus, C. labiatus, C. labratus; Gyalocephalus capitatus; undifferentiated luminal larvae Encysted cyathostomes: late L3 and L4 mucosal cyathostome larvae Ascarids: Parascaris equorum (adults and L4 larval stages) Pinworms: Oxyuris equi (adults and L4 larval stages) Hairworms: Trichostrongylus axei (adults) Large-mouth stomach worms: Habronema muscae (adults) Horse stomach bots: Gasterophilus intestinalis (2nd and 3rd instars), G. nasalis (3rd instars) One dose also suppresses strongyles egg production for 84 days.
-
FOI ucm117074.pdf
Summary
Raise the minimum age limit for use of this product from 4 months up to 6 months of age. -
FOI ucm117068.pdf
Summary
a. New indication: For the treatment and control of Gasterophilus nasalis (3rd instars)
b. Labeling Change: The precautions section is revised to read “This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result.” The photograph on the carton was changed to remove the picture of a young foal. -
Summary
dose level of 0.4 mg moxidectin/kg (2.2 lb) body weight, has been demonstrated to be effective in the treatment and control of the following stages of gastrointestinal parasites of horses and ponies:
Large strongyles: Strongylus vulgaris - (adults and L4/L5 arterial stages), Strongylus edentatus - (adults and tissue stages), Triodontophorus brevicauda - (adults), riodontophorus serratus - (adults)Small strongyles (adults and larvae): Cyathostomum spp. - (adults), Cylicocyclus spp. - (adults), Cylicostephanus spp. - (adults), Gyalocephalus capitatus - (adults), Undifferentiated lumenal larvae
Encysted cyathostomes: Late L3 and L4 mucosal cyathostome larvae
Ascarids: Parascaris equorum - (adults and L4 larval stages)
Pin worms: Oxyuris equi - (adults and L4 larval stages)
Hair worms: Trichostrongylus axei - (adults)
Large-mouth stomach worms: Habronema muscae - (adults)
Horse stomach bots: Gasterophilus intestinalis - (2nd & 3rd instars)
- Quest® Gel (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
FOI UCM457309.pdf
Summary
This supplement supports the safe use in breeding, pregnant, or lactating mares. -
FOI ucm118023.pdf
Summary
The supplement provides for the use of QUEST Plus gel for the treatment and control of adult Cylicocyclus radiatus and Petrovinema poculatus based on results from additional dose confirmation studies. -
FOI ucm118021.pdf
Summary
For the treatment and control of the following stages of gastrointestinal parasites of horses and ponies -
FOI ucm118019.pdf
Summary
For the treatment and control of the following stages of gastrointestinal parasites of horses and ponies six months of age and older and not to be used for food
- Quest® Plus Gel (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis); for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis; and for the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).
- Midamox® for Dogs (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the treatment and control of internal and external parasites of cattle
- Tauramox™ (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
FOI UCM381705.pdf
Summary
This supplement provides for the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs and the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. -
FOI UCM051438.pdf
Summary
ADVANTAGE MULTI for Dogs is indicated for the prevention of heartworm disease caused by Dirofilaria immitis. ADVANTAGE MULTI for Dogs kills adult fleas and is indicated for the treatment of flea infestations ( Ctenocephalides felis). ADVANTAGE MULTI for Dogs is also indicated for the treatment and control of the following intestinal parasites:
FDA page: Open in Animal Drugs @ FDA
-
FOI UCM381709.pdf
Summary
This supplement provides for the prevention of heartworm disease in ferrets caused by Dirofilaria immitis; kills adult fleas ( Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets. -
FOI UCM051423.pdf
Summary
ADVANTAGE MULTI for Cats is indicated for the prevention of heartworm disease caused by Dirofilaria immitis. ADVANTAGE MULTI for Cats kills adult fleas ( Ctenocephalides felis) and is indicated for the treatment of flea infestations. ADVANTAGE MULTI for Cats is also indicated for the treatment and control of ear mite ( Otodectes cynotis) infestations and the following intestinal parasites:
FDA page: Open in Animal Drugs @ FDA
-
FOI ucm117120.pdf
Summary
This supplemental application provides for treatment and control of infections of additional life stages and species of gastrointestinal roundworms for topical use of 0.5% moxidectin solution on cattle. -
FOI ucm117119.pdf
Summary
This supplemental application provides for topical use of a 0.5% moxidectin solution on dairy cattle of breeding age for treatment and control of infections and infestations of certain internal and external parasites. In addition, the regulations are amended to establish a tolerance for moxidectin residues in milk. -
FOI UCM355528.pdf
Summary
Effective in the treatment and control of external parasites. CYDECTIN® (moxidectin) 0.5% Pour-On for Cattle has been proven to effectively control infections and to protect cattle from reinfection with Ostertagia ostertagi for 28 days following treatment and Dictyocaulus viviparus for 42 days after treatment. -
EA 141-099
-
FONSI 141-099
FDA page: Open in Animal Drugs @ FDA
-
FOI UCM117595.pdf
Summary
This supplement provides for the revision of the animal safety information in the warning, precaution, adverse reactions, and post-approval sections of the product labeling. -
FOI ucm117593.pdf
Summary
New indication for the treatment of existing larval and adult hookworm ( Uncinaria stenocephala) infections. -
FOI ucm117588.pdf
Summary
For the prevention of heartworm disease caused by Dirofilaria immitis and for treatment of existing larval and adult hookworm (Ancylostoma caninum) infections.
- ProHeart® 6 (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
FOI ucm051488.pdf
Summary
CYDECTIN Oral Drench for Sheep, when administered at the recommended dose of 0.2 mg moxidectin/2.2 lb (0.2 mg/kg) body weight (BW), is effective in the treatment and control of the adult and larval (L4) stages of the following internal parasites of sheep:
Haemonchus contortus - Adult and L4 larvae
Teladorsagia circumcincta – Adult and L4 larvae
Teladorsagia trifurcata - Adult and L4 larvae
Trichostrongylus axei - Adult and L4 larvae
Trichostrongylus colubriformis - Adult and L4 larvae
Trichostrongylus vitrinus – Adult and L4 larvae
Cooperia curticei - Adult and L4 larvae
Cooperia oncophora – Adult and L4 larvae
Oesophagostomum columbianum - Adult and L4 larvae
Oesophagostomum venulosum – Adult and L4 larvae
Nematodirus battus - Adult and L4 larvae
Nematodirus filicollis - Adults and L4 larvae
Nematodirus spathiger - Adults and L4 larvae
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancylostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxocara cati).
FDA page: Open in Animal Drugs @ FDA
-
Summary
For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). For the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. For the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).
FDA page: Open in Animal Drugs @ FDA
-
Summary
ProHeart (moxidectin) heartworm prevention tablets are indicated for once-a-month use in dogs to prevent infections by the canine heartworm, Dirofilaria immitis, and the subsequent development of canine heartworm disease.
- ProHeart™ (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
FOI ucm118029.pdf
Summary
Addition of six new therapeutic claims:
Trichostrongylus colubriformis – Adult
Cooperia pectinata – Adult
Cooperia spatulata – Adult
Nematodirus helvetianus – Adult
Ostertagia ostertagi – L4
Trichostrongylus axei – L4 -
FOI ucm118028.pdf
Summary
CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the following internal and external parasites of cattle: -
EA 141-220
-
FONSI 141-220
- Cydectin® (ZIP)
FDA page: Open in Animal Drugs @ FDA
-
FOI UCM453544.pdf
Summary
For the prevention of heartworm disease caused by Dirofilaria immitis, and for the treatment and control of Ancylostoma caninum (adults, immature adults, and fourth stage larvae), Uncinaria stenocephala (adults, immature adults, andfourth stage larvae), Toxocara canis (adults and fourth stage larvae), Toxascaris leonina (adults), and Trichuris vulpis (adults) in dogs and puppies that are at least 7 weeks of age and that weigh at least 3 pounds.
- CORAXIS™ (ZIP)
FDA page: Open in Animal Drugs @ FDA
Usage
To prevent infection by the canine heartworm Dirofilaria immitis and the subsequent development of canine heartworm disease. For the treatment and control of the following stages of gastrointestinal parasites in horses and ponies: Large Strongyles : Strongylus vulgaris : (adults and L4 / L5 arterial stages), Strongylus edentatus : (adults and tissue stages), Triodontophorus brevicauda : (adults), Triodontophorus serratus : (adults) Small Strongyles (adults): Cyathostomum spp., including Cyathostomum catinatum , Cyathostomum pateratum Cylicostephanus spp., including Cylicostephanus calicatus , Cylicostephanus goldi , Cylicostephanus longibursatus , Cylicostephanus minutus Cylicocyclus spp., including Cylicocyclus insigne , Cylicocyclus leptostomum , Cylicocyclus nassatus , Cylicocyclus radiatus Coronocyclus spp., including Coronocyclus coronatus , Coronocyclus labiatus , Coronocyclus labratus , Gyalocephalus capitatus , Petrovinema poculatus Small Strongyles : Undifferentiated lumenal larvae Encysted cyathostomes : Late L3 and L4 mucosal cyathostome larvae Ascarids : Parascaris equorum : (adults and L4 larval stages) Pinworms : Oxyuris equi : (adults and L4 larval stages) Hairworms : Trichostrongylus axei : (adults) Large-mouth stomach worms : Habronema muscae : (adults) Horse stomach bots : Gasterophilus intestinalis : (2nd and 3rd instars), Gasterophilus nasalis : (3rd instars) One administration of the recommended dose rate of QUEST (moxidectin) 2% Equine Oral Gel also suppresses strongyle egg production through 84 days. QUEST is indicated for use in horses and ponies, including breeding mares and stallions, and foals six months of age and older. For treatment and control of internal and external parasites: gastrointestinal roundworms ( Ostertagia ostertagi (adult and L4, including inhibited larvae), Haemonchus placei (adult and L4), Trichostrongylus axei (adult and L4), T. colubriformis (adult and L4), Cooperia oncophora (adult and L4), C. pectinata (adult), C. punctata (adult and L4), C. spatulata (adult), C. surnabada (adult and L4), Bunostomum phlebotomum (adult), Oesophagostomum radiatum (adult and L4), Nematodirus helvetianus (adult and L4)); lungworms ( Dictyocaulus viviparus , adult and L4); cattle grubs ( Hypoderma bovis , H. lineatum ); mites ( Chorioptes bovis , Psoroptes ovis ( P. communis var. bovis )); lice ( Linognathus vituli , Haematopinus eurysternus , Solenopotes capillatus , Bovicola ( Damalinia ) bovis ); and horn flies ( Haematobia irritans ). To control infections and to protect from reinfection with H. placei for 14 days after treatment, O. radiatum and O. ostertagi for 28 days after treatment, and D. viviparus for 42 days after treatment.
Source: FDA Animal Drugs @ FDA • Reference
Contraindications
Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result. Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals. Do not use in horses intended for human consumption. A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal.
Side Effects
No approved side-effect narrative is linked yet.
openFDA reaction signals are available for Dog 56 and Cat 56 (view top reported reactions).
Top Reported Reactions (openFDA)
Aggregated reaction terms from FDA openFDA reports (not verified; does not prove causation).
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Adverse Event Case Summaries (openFDA)
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Dog, Crossbred Canine/dog, Male, 4 year, 33.112 kilogram • Drug: MSK, Suspension, Subcutaneous • Reactions: Lack of efficacy (endoparasite) - heartworm • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-056101
- Serious AE: Yes
- Treated For AE: No
- Sex: Male
- Age: 4.00 Year
- Weight: 33.112 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Subcutaneous
- Form: Suspension
Dog, Spaniel - Cocker American, Male, 2.83 year, 10.43 kilogram • Drug: MSK, Solution, Topical, Dose: 1 tube per animal • Reactions: Loose stool, Lack of efficacy (ectoparasite) - flea • Outcome: Outcome Unknown
- Report ID: USA-USFDACVM-2025-US-055969
- Serious AE: No
- Treated For AE: No
- Sex: Male
- Age: 2.83 Year
- Weight: 10.430 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Topical
- Form: Solution
- Dose: 1 tube per animal
Dog, Bulldog - French, Female, 2 year, 13.608 kilogram • Drug: MSK, Suspension, Subcutaneous, Dose: 0.72 mL per animal • Reactions: Lack of efficacy (endoparasite) - hookworm • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-054879
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Female
- Age: 2.00 Year
- Weight: 13.608 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Subcutaneous
- Form: Suspension
- Dose: 0.72 mL per animal
Dog, ['Spaniel - Cocker American', 'Poodle (unspecified)'], Male, 10 year, 4.491 kilogram • Drug: MSK, Suspension, Subcutaneous, Dose: 0.23 mL per animal, Frequency: 1 per year • Reactions: Lack of efficacy (endoparasite) - hookworm • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-055178
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 10.00 Year
- Weight: 4.491 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Subcutaneous
- Form: Suspension
- Dose: 0.23 mL per animal
- Frequency: 1 per year
Cat, Domestic Shorthair, Female, 2 year, 3.63 kilogram • Drug: MSK, Solution, Topical, Dose: 1 tube per animal • Reactions: Foaming at the mouth, Licking at application site • Outcome: Recovered/Normal
- Report ID: USA-USFDACVM-2025-US-055996
- Serious AE: No
- Treated For AE: No
- Sex: Female
- Age: 2.00 Year
- Weight: 3.630 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Topical
- Form: Solution
- Dose: 1 tube per animal
Dog, ['Great Pyrenees', 'Dog (unknown)'], Male, 2 year, 34.428 kilogram • Drug: MSK, Suspension, Subcutaneous, Dose: 1.45 mL per animal • Reactions: Lack of efficacy (endoparasite) - heartworm • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-055117
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 2.00 Year
- Weight: 34.428 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Subcutaneous
- Form: Suspension
- Dose: 1.45 mL per animal
Dog, Retriever - Labrador, Male, 11 year, 29.756 kilogram • Drug: MSK, Suspension, Subcutaneous, Dose: 1.60 mL per animal • Reactions: Lack of efficacy (endoparasite) - heartworm, Medication error NOS • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-054859
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 11.00 Year
- Weight: 29.756 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Subcutaneous
- Form: Suspension
- Dose: 1.60 mL per animal
Dog, Boxer (German Boxer), Male, 8 year, 33.112 kilogram • Drug: MSK, Suspension, Subcutaneous, Dose: 1.65 mL per animal • Reactions: Lack of efficacy (endoparasite) - tapeworm, Intentional misuse • Outcome: Ongoing
- Report ID: USA-USFDACVM-2025-US-054867
- Serious AE: Yes
- Treated For AE: Yes
- Sex: Male
- Age: 8.00 Year
- Weight: 33.112 Kilogram
- Case-reported brand: MSK
- Case-reported manufacturer: MSK
- Route: Subcutaneous
- Form: Suspension
- Dose: 1.65 mL per animal
Data source: FDA openFDA Animal & Veterinary adverse event reports.
Overdose Information
No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.
Storage & Handling
No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.
Share Your Thoughts
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.